EGAGenomicsIllumina HiSeq 2000;ILLUMINAhttps://ega-archive.org/datasets/EGAD000010032317EGA dataset EGAD00001003231EGA<h4>Background & aims</h4>The differentiation of distinct multifocal hepatocellular carcinoma (HCC): multicentric disease vs. intrahepatic metastases, in which the management and prognosis varies substantively, remains problematic. We aim to stratify multifocal HCC and identify novel diagnostic and prognostic biomarkers by performing whole genome and transcriptome sequencing, as part of a multi-omics strategy.<h4>Methods</h4>A complete collection of tumour and somatic specimens (intrahepatic HCC lesions, matched non-cancerous liver tissue and blood) were obtained from representative patients with multifocal HCC exhibiting two distinct postsurgical courses. Whole-genome and transcriptome sequencing with genotyping were performed for each tissue specimen to contrast genomic alterations, including hepatitis B virus integrations, somatic mutations, copy number variations, and structural variations. We then constructed a phylogenetic tree to visualise individual tumour evolution and performed functional enrichment analyses on select differentially expressed genes to elucidate biological processes involved in multifocal HCC development. Multi-omics data were integrated with detailed clinicopathological information to identify HCC biomarkers, which were further validated using a large cohort of HCC patients (n = 174).<h4>Results</h4>The multi-omics profiling and tumour biomarkers could successfully distinguish the two multifocal HCC types, while accurately predicting clonality and aggressiveness. The dual-specificity protein kinase TTK, which is a key mitotic checkpoint regulator with links to p53 signaling, was further shown to be a promising overall prognostic marker for HCC in the large patient cohort.<h4>Conclusions</h4>Comprehensive multi-omics characterisation of multifocal tumour evolution may improve clinical decision-making, facilitate personalised medicine, and expedite identification of novel biomarkers and therapeutic targets in HCC.Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis.Miao Ruoyu R, Luo Haitao H, Zhou Huandi H, Li Guangbing G, Bu Dechao D, Yang Xiaobo X, Zhao Xue X, Zhang Haohai H, Liu Song S, Zhong Ying Y, Zou Zhen Z, Zhao Yan Y, Yu Kuntao K, He Lian L, Sang Xinting X, Zhong Shouxian S, Huang Jiefu J, Wu Yan Y, Miksad Rebecca A RA, Robson Simon C SC, Jiang Chengyu C, Zhao Yi Y, Zhao Haitao HP130CAS, P130Cas, CAS1, DmelCG2102, l(3)neo33, Data Set, Crkas, p120, anon-Pen19, cold antibody hemolytic anemia, P120CAS, Xpo2, XPO2, l(2)02029, das, p19, l(2)k03902, BcDNA:GM09207, BcDNA:LD14270, 2610100P18Rik, CTNND, p120(CTN), anemia, CG2102, Dcas, cold antibody disease, TFIID, Cas, CAS, developmental verbal apraxia, EWSR1, SARFH, Enb, CRKAS, ENA, Ena, p120(ctn), Sarfh, Caz, CG15112, speech-language disorder-1, ENA/VASP, Vasp, AA407533, DmelCG15112, ENHANCER OF ATNSI ACTIVITY, developmental apraxia of speech, cold antibody hemolytic anaemia, NDPP1, speech-language disorder 1, CG13281, cold antibody, cas, CASS1., enb, SPCH1, CG3606, pen19, P120CTN, l(3)j1C2, hemolytic, dcas, VASP, p120(CAS), DmelCG13281, CSE1, ming, articulatory apraxia, Capts, MENA, AI385681, DmelCG3606, p120 catenin, p120(cas), Pen19, P19, Cadherin-associated Src substrateCarcinoma, Poly(rA), Transcriptome, Undifferentiated Carcinoma, epithelioma, Transcriptome Profile, Neoplasms, Expression Profiles, "carcinoma" EXACT [CSP2005:2000-1867], Spindle-Cell., Gene Expression Profile, Gene, Malignant Epithelial Tumors, "carcinoma, Profiles, Tumor, Epithelial Tumors, Malignant, Anaplastic, Gene Expression, Undifferentiated Carcinomas, "epithelial carcinoma" EXACT [NCI2004_11_17:C2916], epithelial cancer, Epitheliomas, Expression Signatures, "carcinoma NOS (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:189549006], Gene Expression Signatures, Polynucleotides, Neoplasm, Spindle-Cell Carcinomas, sequence, Malignant Epithelial Neoplasms, no subtype (morphologic abnormality)" EXACT [SNOMEDCT_2005_07_31:68453008], Gene Expression Signature, Malignant Epithelial, Epithelioma, Carcinomatosis, Expression Profile, Carcinomatoses, Transcriptome Profiles, Carcinomas, Anaplastic Carcinoma, Spindle-Cell Carcinoma, Undifferentiated, Spindle Cell, Profile, homopolymer, Epithelial Neoplasms, Epithelial Neoplasm, Signatures, 5'-Adenylic acid, Polyadenylic Acids, primary structure of sequence macromolecule, Adenine, Adenine Polynucleotides, Expression Signature, Gene Expression Profiles, Transcriptomes, Malignant Epithelial Neoplasm, Anaplastic Carcinomas, malignant Epithelioma, Malignant Epithelial Tumor, Signature, Epithelial TumorBiomarker, Biological Markers, Viral Marker, Serum Marker, Viral, Surrogate Endpoints, Clinical, Surrogate Endpoint, End Points, determination, Clinical Markers, Laboratory, hepatitis B virus related hepatocellular carcinoma, Surrogate, Clinical Marker, Biological Marker, Serum Markers, Endpoints, Biochemical, End Point, chemical analysis., Endpoint, Biochemical Markers, Immunologic, Serum, Laboratory Marker, Biologic Marker, Surrogate Marker, Immune Marker, Surrogate End Points, hepatitis B virus-related hepatocellular carcinoma, Surrogate Markers, Laboratory Markers, Immunologic Markers, Immune, Markers, Biochemical Marker, Marker, Biological, Surrogate End Point, Viral Markers, assay, Immunologic Marker, Biologic, Biologic Markers, Immune MarkersUVO Gene Mutation, dp53, Disorders, H. pylori Positive, Materials, Selenium and Vitamin E Efficacy Trial, 0438/31, dDYRK2, Particle, tissue specimen, Liver Cell Carcinoma, ERBB2 Amplification, CDK5/p23, Medical Specialties, Positive Charge, copy_number, RET/PTC Rearrangement, Hepatitis C Virus RNA Positive, p53 Mutation, Biological, PGR Positive, [Tau protein] kinase activity, Transcriptome Sequencing, myd, Decision-Making, Methylated MGMT Promoter, Selection, ERA Positive, Biologic Drugs, G Protein Subunit Alpha q Gene Mutation, Involvement, like-acetylglucosaminyltransferase, tau-protein kinase II activity, IDH Gene Mutation, CD324 Gene Mutation, Hepatitis B Virus Core Antibody Positive, 0037/17, c-KIT Positive, beta-Tub6D, Flavoprotein Subunit of Complex II Positive, dmp53, adult primary hepatocellular carcinoma, HLD5, Human hepatitis B virus, T, B7H1 Positive, BEK Gene Mutation, procedures, Evolution, node-positive, Cadherin 1 Gene Mutation, ESTRB Positive, XH2 Gene Mutation, Supervision, Prognosis Marker, Biological Medicine, Catenin Beta 1 Gene Mutation, ER Beta Positive, intrahepatic, cdk5/p20, Homo sapiens disease, Telomerase Reverse Transcriptase Gene Promoter Mutation, CG17117, CXXC finger protein 9, l(3)02667, Methylated MGMT Gene Promoter, Clonality, screening, Liver, hepatitis B virus, anatomical protrusion, Human Immunodeficiency Virus Positive, Biologic Products, KGFR Gene Rearrangement, c-erbB2 Gene Amplification, Multifocal Lesion, B-RAF Gene Rearrangement, Management Occupations, Anti-HBc Positive, ttk/FTZ-F2, Hepatitis B Virus Surface Antibody Positive, COMOROS, copy number, Estrogen Receptor Alpha Positive, APC1, Medical Speciality, DmIKKgamma, Representation, SDHIP Positive, Clinical Decision Making, Marker, dIKK, mKIAA0609, Obtain, Molecular Marker of Prognosis, Dx, FGFR-2 Gene Rearrangement, FLT2 Gene Mutation, FGFR-1 Gene Rearrangement, tau protein kinase activity, RET Gene Rearrangement, HTH, Carcinomas, Enrichment, NRAS Gene Mutation, Non-Neoplastic, ECAD Gene Mutation, IKK-gamma, CG3401, beta3Tub, Biologics, Immunologic, whole genome, EST2 Promoter Mutation, Laboratory Marker, Present, ESR Positive, PDCD1L1 Positive, Multiple, MDC1D, Positive EBV Serum Test, IDH Gene Family Mutation, enr, Diseases and Disorders, Info, N-RAS Gene Mutation, HER2/Neu Amplification, WHOLE TRANSCRIPTOME SEQUENCING, FTZ-F2, KRAS Gene Mutation, Expression of PD-L1, HYCC1, SDHF Positive, Nuclear Receptor Subfamily 3 Group A Member 2 Positive, TTK69, Biologic Pharmaceuticals, BRCA1-Associated Protein 1 Gene Mutation, CDHE Gene Mutation, Hepatitis, 143391_i_at, Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, beta3 TU, Hepatitis B Virus Surface Antigen Positive, l(3)05745, IH, Aim, Enrich, Adult Liver Cancer, 1418/06, G Protein Subunit Alpha 11 Gene Mutation, Medical, Technique, B7-H Positive, cell differentiation, Cadherin-Associated Protein, Clinical, MGMT Gene Methylation, Hepatitis B Core Antibody Positive, STK31, AIMS01, BEK Gene Rearrangement, Study, API6, Hepatic Parenchyma, RET Rearrangement, KM, drugs, RAD54 Homolog Gene Mutation, Multi, SELECT, genome, RNA-Seq, beta[[3]]-tubulin, HER-2 Gene Amplification, Differentiation, Including, esk, Pharmaceuticals, New, Positive EBV Test, Choice, findings, Biologic Medicines, PR Positive, Serum Markers, Hepatitis B Surface Protein Antigen Positive, prac, disorders, Estrogen Receptor Positive, Factor, Immune Marker, hepatitis B virus (HBV), B-RAF1 Gene Rearrangement, ATRX, BRAF Gene Rearrangement, condition, Expression Positive, FLG Gene Mutation, PAX8 Rearrangement, Androgen Receptor Positive, HGFR Gene Amplification, ESR1 Positive, hepatitis B virus HBV, MET Gene Amplification, c-MET Gene Amplification, ftzf2/ttk, CXXC9, ER-Alpha Positive, Copy Number, Methylated MGMT, Ttk, Abnormal Involuntary Movement Scale Clinical Classification, Dmikkgamma, ERG Rearrangement, HBsAg Positive, WTSS, Dm-P53, Negated, CG16910, CLONALITY, Prognostic Marker, TERT Gene Promoter Mutation, Tub, No, Ret Proto-Oncogene Rearrangement, l(3)j7B8, signalling process, betatub60D, IDH Mutation, 1p/19q Co-deletion, ttkp69, SDHA Positive, Q Polypeptide Gene Mutation, disease_term, Strategy, Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Representative, Estrogen Receptor 2 Positive, mRNA Expression, XNP Gene Mutation, O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation, Biological Markers, Viral Marker, ER Positive, single-organism developmental process, 0250/25, v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement, Expression Detected, Endpoint, Hepatomas, Intrahepatic, protein expression, Tp53, HRAS1 Gene Mutation, G-ALPHA-q Gene Mutation, BAP1 Gene Mutation, Laboratory Markers, Techniques, DMP53, Clonal, Specialities, Managing, Details, v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation, IKKg, TP53, Abnormal, gene expression, KEY, Total RNA Sequencing, 1323/07, DRCTNNB1A, human disease, Prognoses, Estrogen Receptor Beta Positive, twk, Identification, Natural, Whole Transcriptome Sequencing, DOG1 Positive, Esk1, Adult, Elected, Biological Drugs, ETV Family Gene Rearrangement, Ets Variant Family Rearrangement, FLT2 Gene Rearrangement, Rearrangement identified, Novel, Homologous Serum, FGFR3 Gene Rearrangement, Immune, ECT1 Gene Mutation, Estrogen Receptor 1 Positive, Fibroblast Growth Factor Receptor 2 Gene Mutation, Other Disease, IDH Family Mutation, CD333 Gene Rearrangement, Choose, Select, Managed, ATRX Gene Mutation, ERG Gene Rearrangement, Specialties, brain protein kinase PK40erk activity, gyltl1b-b, Liver Cell, Biochemical Markers, HER2 Gene Mutation, somatic, results, Gene Expression, Hepatitis B Surface Antibody Positive, Involved, Non, Biopharmaceuticals, Kenny, HIV Positive, Not, Biologic Product, Adult Liver, KIAA0609, Tub60D, HIV positive, 1p/19q Codeletion, POSITIVE, ADCADN, beta-tub, Guanine Nucleotide Binding Protein (G Protein), Yes, Factors, TTK88, Prognostic, SDH2 Positive, Detailed, ERBB2 Gene Mutation, Picked, Methodological Study, Treatments, disease, DmelCG16910, Expressed, Biochemical Marker, ER-Beta Positive, Election, P53, Selenium and Vitamin E Cancer Prevention Trial, p44, HRAS Gene Mutation, Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Total RNA-Seq, BRAF Rearrangement, Non-, Mps1, CDH1 Gene Mutation, MULTIFOCAL, Procedures, p50, Cellular Differentiation, Clinical Markers, p53, clonality, Anti-HBs Positive, c-erbB2 Gene Activation, Gyltl1a, Surrogate End Points, Cell Carcinomas, Surrogate Markers, Fp Positive, Fibroblast Growth Factor Receptor 1 Gene Rearrangement, OGD Gene Mutation, Differentiated, Anti-HBcAb Positive, Studies, Hep C RNA Positive, Dane, CG1856, IKK[[gamma]], ATP:protein phosphotransferase (Ser/Thr- and Tyr-phosphorylating) activity, CD274 Antigen Positive, glycogen synthase kinase-3beta activity, Epithelial Gene Mutation, MET Proto-Oncogene, tau kinase activity, clone 2.13, DIAG, SWS Gene Mutation, TAOS2 Positive, D.m.BETA-60D, Biological Marker, 1119/04, Natural Product, Liver Cancers, Methylguanine-DNA Methyltransferase Gene Promoter Methylation, Administration, Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation, H-ras Gene Mutation, GDC Clonality Terminology, Immunologic Markers, ETV Gene Rearrangement, IKK, Clients, Disorder, CD332 Gene Rearrangement, Ets Variant Gene Family Rearrangement, CLK1, disorder, RNA Sequencing, HER2 Gene Amplification, beta3-tubulin, TRP53, Immunologic Marker, CTNNB Gene Mutation, progesterone receptor positive, RASH1 Gene Mutation, human hepatitis B virus HBV, beta-Tub60D, Dm-HTH, Anti-Hepatitis B Virus Core Antibody Positive, Medical Specialty, MULTIPLE, beta3-Tub, medical condition, Xp53, NR3A2 Positive, MGMT Gene Promoter Methylation, dual-specificity protein kinase, MPS1L1, TMEM16A Positive, Catenin Beta-1 Gene Mutation, MGMT Methylation, AR Positive, Performed, Serum Marker, FMS-Like Tyrosine Kinase 2 Gene Mutation, HIV Positivity, Mast/Stem Cell Growth Factor Receptor Kit Positive, E(yan)100D, Cell Differentiation Process, FGFR-2 Gene Mutation, l(3)86Ca, patient, Calcium-Dependent Adhesion Protein, introduction, Drug, Oversight, Therapeutic, Hepatocellular, Aims, TTKA, HBs Antigen Positive, CD274 Molecule Positive, Treatment, methodology, GTPase Gene Mutation, Anti-HBsAb Positive, Beta Gene Mutation, Surrogate Endpoints, Product, Date of Diagnosis, Laboratory, RNA-seq (transcriptome sequencing), acetylglucosaminyltransferase-like protein, Progesterone Receptor Positive, growth and development, adult hepatoma, Diagnosis, FGFBR Gene Rearrangement, Integrated, Mutations, ftz-f2, Method, bbl, symptoms, Nuclear Receptor Subfamily 3 Group A Member 1 Positive, Biological Product, Comoros, Erg-3 Gene Rearrangement, CD332 Gene Mutation, Ha-ras Gene Mutation, EXPRESSED, HRas Proto-Oncogene, 3540, Genomes, BCC7, TRT Promoter Mutation, 0702/07, Matched, GAQ Gene Mutation, Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification, Mbp-1, 1422/04, FGFR1 Gene Rearrangement, PD-L1+, Selected, Hepatocellular Carcinoma, NEU Gene Mutation, 1260/10, v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement, Pick, FGFR3 Gene Mutation, SDHB Positive, Dp53, medicine, K-RAS Mutation, CD331 Gene Rearrangement, COPYNUM, Medicine, C-HA-RAS1 Gene Mutation, MET Amplification, ZNF-HX Gene Mutation, Biologic Drug, Comprehensive, p50/tubulin, ERBB2 Gene Amplification, single organism signaling, Beta Catenin Gene Mutation, CG10873, Viral, Diagnosed, Procedure, Arabidopsis dual specificity kinase 1 activity, Alpha 11 Gene Mutation, disease_type, CD331 Gene Mutation, ERB Positive, Cadherin, JKT4 Gene Rearrangement, bfy, ADK1, CMC1 Gene Mutation, Hth, fg, P53 Gene Mutation, End Points, Hepatoma, Biological Medicines, Guanine Nucleotide-Binding Protein, PAX8 Gene Rearrangement, Biological Drug, NR3A1 Positive, signs, beta3TUB, Keratinocyte Growth Factor Receptor Gene Rearrangement, Methodological, HER2 Amplification, Hepatic Tissue, Genomic, GSK, CD333 Gene Mutation, Positive Epstein-Barr Virus Test, DTB3, Material, RNAseq, Whole-Transcriptome Sequencing, FGFBR Gene Mutation, TCS1 Promoter Mutation, bhy, Hepatocellular., CG31325, BFGFR Gene Mutation, beta[[3]]-Tub, DmelCG17117, Clinical Marker, HCV RNA Positive, Prognostic Factors, Ttk69, tramtrak, Cell Differentiation, LFS1, LARGE1, dIKK-gamma, Mps1p, ER+, Receptor Tyrosine Kinase Gene Amplification, 1184/16, AIM, FGFR1 Gene Mutation, 5311, Medical Specialities, Structural, p55 Gene Rearrangement, FLG Gene Rearrangement, PDCD1LG1 Positive, DmIKK-gamma, disease or disorder, anon-EST:Liang-2.13, B virus, Biologicals, Multifocal, DNMT1, ETV Rearrangement, androgen receptor positive, Negation, HBs Positive, Diagnostic, Liver Cancer, DNMT1_HUMAN, Positive Number, MDDGB6, TPK, positive test result, v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation, GNAQ Gene Mutation, Structure, ESK, PD-L1 Positive, COM, CTNNB1 Gene Mutation, PERFORMED, FGFR2 Gene Rearrangement, ANO1 Positive, RAD54 Gene Mutation, Medical Decision Making, Expression, Insurance, Testis-specific gene 24 protein, Biologic, TPK I, Cancer, 1325/15, DNA (cytosine-5)-methyltransferase 1, CD117 Positive, FGFR2 Gene Mutation, Products, Perform, Dmbeta3, Helicobacter pylori Positive, whole blood, ESRB Positive, Matching, beta3t, Dane Particle, Hepatitis Virus, MCMT, Positive Finding, IKKgamma, CG11558, diagnosis, AL022661, Surrogate End Point, GNA11 Gene Mutation, p53/tubulin, Biopharmaceutical, background, Hepatocyte Growth Factor Receptor Gene Amplification, Detail, Biologic Markers, Represent, CG33336, differentiation, ATP:tau-protein O-phosphotransferase activity, 5125, Hepatocellular carcinoma, CT-2, TTK, HBcAb Positive, Surrogate, Information, Match, Intrahepatic Route of Administration, disease term, Endpoints, Tumor Protein p53 Gene Mutation, postnatal growth, D-p53, Cancers, IP Positive, beta3, Hepatitis B Surface Antigen Positive, CXXC-type zinc finger protein 9, dtl, N-RAS Mutation, FLT-2 Gene Mutation, LAB_SEQ_METHOD, ETS Transcription Factor ERG Gene Rearrangement, like-glycosyltransferase, MPH1, CEK Gene Mutation, Alpha-11 Gene Mutation, Chromatin Remodeler Gene Mutation, CLEC2C, Immune Markers, Hepatitis B, Fibroblast Growth Factor Receptor 1 Gene Mutation, HSN1E, postnatal development, Hepatitis C Viral RNA Positive, Biochemical, Mbp1, FLT-2 Gene Rearrangement, JKT4 Gene Mutation, Serum, AR+, KRAS Mutation, betaTub3, disease type, Speciality, ESR-Beta Positive, Fibroblast Growth Factor Receptor 2 Gene Rearrangement, FGFR-3 Gene Rearrangement, diseases, diseases and disorders, Dmp53, KGFR Gene Mutation, Obtained, Key, estrogen receptor positive, Copy Number Reported, 1209/10, Insurance Medicine, Protein Expression, Medical Decision-Making, Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation, DmP53, tau-protein kinase I activity, File Validated, B3t, c-Met Gene Amplification, DmelCG3401, Markers, Methodological Studies, PR+, FMS-Like Tyrosine Kinase 2 Gene Rearrangement, 1209/05, Viral Markers, Anti-Hepatitis B Core Antibody Positive, B7 Homolog 1 Positive, TPK II, Therapies, Beta 1 (88kD) Gene Mutation, Positive, Medicines, tau-tubulin kinase activity, protein threonine/tyrosine kinase activity, Therapy, Carcinoma, Surrogate Endpoint, Anti-HBs Antibody Positive, TP53 Gene Mutation, INTRAHEPATIC, 1p/19q co-deletion, KIT Proto-Oncogene Tyrosine Protein Kinase Positive, v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation, Positive Estrogen Receptor, Biologic Marker, HBV, HBsAb Positive, K-SAM Gene Mutation, 3t, Succinate Dehydrogenase Complex Flavoprotein Subunit A Positive, dual-specificity kinase activity, clone 2.9, HCC, MDDGA6, Diseases, Specialty, Genetic Materials, Succinate Dehydrogenase Complex Iron Sulfur Subunit B Positive, Liver Tissue, KRAS2 Gene Mutation, Genetic Material, acetylglucosaminyltransferase-like 1A, anon-EST:Liang-2.9, Mitotic checkpoint regulator, gyltl1b, Paired Domain Gene 8 Gene Rearrangement, UNQ203/PRO229, Representational, DNA (cytosine-5-)-methyltransferase 1, 174, mdc1d, DmelCG33336, Programmed Cell Death 1 Ligand 1 Positive, ESR2 Positive, l(3)j2A1, Hepatitis C RNA Positive, LARGE_HUMAN, Ttk88, Multicentric, Type 1, Identified, Insurance Medicines, Positive Laboratory Test Result, Paired Box 8 Gene Rearrangement, hth1, LCAM Gene Mutation, hth2, Patient, spine, E-Cadherin Gene Mutation, 1372/08, Cistron, Hepatocellular Carcinomas, Arc-1 Gene Mutation, N-SAM Gene Mutation, N-SAM Gene Rearrangement, betaTub, Prognostic Factor, CD274 Positive, other disease, MPS1, osn, Material Identification, KRAS-2 Gene Mutation, oss, PDL1 Positive, Cell Carcinoma, Gene, KIT Positive, Anti-HBc Antibody Positive, TERT Promoter Mutation, KAL2 Gene Mutation, ECT1 Gene Rearrangement, froggy, protrusion, protein tau kinase activity, 1396/14, Anoctamin-1 Positive, FGFR-3 Gene Mutation, Liver Cell Carcinomas, Anti-Hepatitis B Virus Surface Antibody Positive, Whole Transcriptome Shotgun Sequencing, dmIKKgamma, HIV test positive, Drugs, Biomarker, Somatic, Erb-B2 Receptor Tyrosine Kinase Gene Mutation, BFGFR Gene Rearrangement, Genetic, Fibroblast Growth Factor Receptor 3 Gene Mutation, Cadherin 1, CT96, E-Cadherin (Epithelial) Gene Mutation, HER2/neu Gene Mutation, LARGE, BRCA1 Associated Protein 1 Gene Mutation, v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive, Positive Surgical Margin, non-neoplastic, BPFD#36, Trp53, Positive Lymph Node, PYT, ovs, Cyclosome subunit 1, C-H-RAS Gene Mutation, betaTub60C, OGD Gene Rearrangement, ttk69, KAL2 Gene Rearrangement, SDH1 Positive, ER Alpha Positive, DNA MTase HsaI, date of diagnosis, UCHL2 Gene Mutation, RAD54L Gene Mutation, Disease, GNA-11 Gene Mutation, Hepatitis B viruses, CEK Gene Rearrangement, DmelCG1856, BETA 60D, DNMT, date_of_diagnosis, End Point, Tree, Loss of Chromosomes 1p/19q, Cistrons, Client, ESTRR Positive, K-SAM Gene Rearrangement, DIAGNOSIS, viruses, development, del(1p/19q), DNA methyltransferase HsaI, Fibroblast Growth Factor Receptor 3 Gene Rearrangement, Disease or Disorder, techniques, ESRA Positive, beta[[3]] tubulin, Chose, ERBB2 Mutation, ETV Family Rearrangement, distinct, Adult Liver Cancers, Beta-Catenin Gene Mutation, GA11 Gene Mutation, Paired Box Gene 8 Gene Rearrangement, TP2 Promoter Mutation, AIMS, Chosen, ORAOV2 Positive, beta60C, validated, 1281/04, Surrogate Marker, BAP1 Mutation, 1049/07, Meis1, c-K-ras Gene Mutation, Management, FGFR-1 Gene Mutation, Natural Products, Inclusive, growth, Mitochondrial Positive, Genome, m.HsaI, Positive Margins, glycosyltransferase-like protein LARGE1falseena-DATASET-CAS_CN-17-03-2017-16:16:33:917-247 - samplesPoly A transcriptome sequence of mutifocal hepatocelular carcinoma2017-07-26 15:39:29EGAD00001003231960624859455EGAC00001000070EGAS00001002337